Skip to main content

Dextroamphetamine News

FDA Medwatch Alert: FDA Requires Expanded Labeling About Weight Loss Risk in Patients Younger Than 6 Years Taking Extended-Release Stimulants for ADHD

FDA Drug Safety Communication - June 30, 2025 What safety concern is FDA announcing?The U.S. Food and Drug Administration (FDA) is revising the labeling of all extended-release stimulants indicated...

ADHD Stimulants Can Be Safely Prescribed Via Telehealth, Study Argues

MONDAY, June 16, 2025 — People with ADHD might be prescribed their meds remotely without increasing their risk of addiction, a new study says. Experts have worried that prescribing stimulants like A...

FDA Medwatch Alert: FDA Updating Warnings to Improve Safe Use of Prescription Stimulants Used to Treat ADHD and Other Conditions

What safety concern is FDA announcing? To address continuing concerns of misuse, abuse, addiction, and overdose of prescription stimulants, the U.S. Food and Drug Administration (FDA) is requiring...

FDA Approves Xelstrym (dextroamphetamine) Transdermal System for the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)

Miami, FL and Jersey City, NJ - March 23, 2022 --Noven Pharmaceuticals, Inc., awholly-ownedsubsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced that the U.S. Food and Drug Administration...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Attention-Deficit Hyperactivity Disorder (ADHD), Sexual Dysfunction, SSRI Induced, Narcolepsy, Fatigue, Drowsiness

Dextroamphetamine patient information at Drugs.com